$Clene (CLNN.US)$ on 29 Feb new exiting data will be presented at ACTRIMS Forum 2024.

$Intuitive Machines (LUNR.US)$ last year the stock climed 40 just using the rumours as a ladder. This time it was a real rocket to the sky.

$Cogent Biosciences (COGT.US)$ new data is comin for mastocytosis, the presentation is scheduled at AAAAI conference in a couple of days. And bezuclastinib soon will be a new standard of care for GIST.

$ARS Pharmaceuticals (SPRY.US)$ new data will be presented at AAAAI meeting 23-26 Feb 2024

$BioCardia (BCDA.US)$ 04 March 2024 new data from phase 3 and phase 1/2 trials will be presented at the Technology and Heart Failure Therapeutics Conference.

$Sangamo Therapeutics (SGMO.US)$ 22 Feb 2024 positive results of IL23R - CAR will be announced at the ECCO 2024 meeting

$Ventyx Biosciences (VTYX.US)$ 22 Feb 2024 Phase 2 positive results will be announced : VTS002 has been proven as well tollerated, met all primary and secondary endpoints, and has been found statistically superior to placebo.

$Akebia Therapeutics (AKBA.US)$ 27 March - FDA approvale date. Vadadustat will be approved this time for the US market.

$Grifols (GRFS.US)$ today announced positive topline results from AdFirst phase 3 study confirming the efficacy of fibrinogen concentrate in reducing intraoperative blood loss.

$SeaStar Medical (ICU.US)$  FDA approval and a commence of the product are coming.